Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TLRY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTilray reports record $915M revenue, guides FY2027 adjusted EBITDA to $68M-$75M
Filed July 28, 2026 · Period ending July 28, 2026 · ~1 min read
Key Changes
-
high
FY2026 revenue rose 11% to $915.5M with adjusted EBITDA of $61.1M (up 11% YoY); company reduced net debt to $0.7M and ended year with ~$235M in cash and marketable securities.
Exhibit 99.1 view on EDGAR → -
high
Guides FY2027 adjusted EBITDA to $68M-$75M (double-digit growth) and expects over $1B in annual revenue.
Exhibit 99.1 view on EDGAR → -
high
International medical cannabis revenue grew 34% in FY2026; CC Pharma pharmaceutical distribution gross profit increased 57% in Q4, demonstrating operating leverage.
Exhibit 99.1 view on EDGAR → -
high
BrewDog acquisition creates pro forma global beverage platform of ~$500M; company has stabilized the business and positioned it for profitability in first few months of ownership.
Exhibit 99.1 view on EDGAR → -
medium
Evaluating multiple pathways to participate in federally compliant U.S. medical cannabis market following rescheduling developments; has developed blueprint for U.S. Tilray Medical platform focused on research and compliant medical access.
Exhibit 99.1 view on EDGAR →
Summary
Tilray delivered record fiscal 2026 results with revenue of $915.5 million (up 11% year-over-year), adjusted EBITDA of $61.1 million (up 11%), and a dramatically improved balance sheet—net debt fell to just $0.7 million while cash and marketable securities reached approximately $235 million. The company's international medical cannabis segment grew revenue 34%, with CC Pharma's pharmaceutical distribution gross profit surging 57% in the fourth quarter, demonstrating meaningful operating leverage in its European infrastructure. The BrewDog acquisition creates a pro forma $500 million global beverage platform, which management has stabilized and positioned for profitability in the first months of ownership.
Combined with Tilray's American craft beer portfolio and Carlsberg partnership, this establishes a scaled beverage business alongside the company's cannabis and wellness operations. For fiscal 2027, Tilray guides adjusted EBITDA to $68 million to $75 million (double-digit growth) and expects to exceed $1 billion in annual revenue. The company is also evaluating pathways into a federally compliant U.S. medical cannabis market following recent rescheduling developments, though regulatory uncertainty remains with ongoing legal challenges.
Section-by-Section Diff
Event · Exhibit 99.1
Tilray reports record FY2026 revenue of $915M, adjusted EBITDA of $61M, and guides FY2027 adjusted EBITDA to $68M-$75M.
Added in current filing · view on EDGAR →
Net revenue increased 11% to $915.5 million in fiscal 2026 compared to $821.3 million.
Gross profit increased 8% to $260.4 million compared to $240.6 million. ... Adjusted EBITDA5 was $61.1 million in fiscal 2026 compared to $55.0 million
Tilray delivered record fiscal 2026 revenue of $915.5 million (up 11% year-over-year), gross profit of $260.4 million (up 8%), and adjusted EBITDA of $61.1 million (up 11% from $55.0 million). The company reduced net debt to $0.7 million and ended the year with approximately $235 million in cash, restricted cash, and marketable securities. Adjusted net income nearly doubled to $12.2 million from $6.5 million, while GAAP net loss was $105.2 million driven predominantly by non-cash charges.
Added in current filing · view on EDGAR →
Tilray accelerated its beverage strategy through the acquisition of BrewDog, creating a pro forma global beverage platform of approximately $500 million and adding one of the world's leading craft beer and hospitality brands. In just a few months of ownership, Tilray has stabilized the business, improved performance and positioned BrewDog for profitability
Tilray acquired BrewDog, creating a pro forma global beverage platform of approximately $500 million. The company has stabilized BrewDog in the first few months of ownership and positioned it for profitability. This acquisition, combined with Tilray's American craft beer portfolio and exclusive U.S. partnership with Carlsberg, creates a scaled global beverage platform with significant growth opportunities.
Added in current filing · view on EDGAR →
For its fiscal year ending May 31, 2027, the Company expects to achieve adjusted EBITDA5 of $68 million to $75 million, representing double digit growth as compared to fiscal year 2026.
Tilray guides fiscal 2027 adjusted EBITDA to $68 million to $75 million, representing double-digit growth from fiscal 2026's $61.1 million. The company expects over $1 billion in annual revenue for fiscal 2027. Management emphasizes continued momentum across its diversified platform spanning cannabis, beverage, hospitality, and wellness.
Added in current filing · view on EDGAR →
Following recent U.S. rescheduling developments, Tilray continues to evaluate multiple pathways to participation in an emerging federally compliant, science-driven medical cannabis market. ... Tilray has already developed a blueprint for a U.S. Tilray Medical platform that is focused on research, education, cannabinoid-based medicine development, patients and compliant medical cannabis access rather than adult-use retail.
Tilray is evaluating multiple pathways to participate in a federally compliant U.S. medical cannabis market following recent rescheduling developments. The company has developed a blueprint for a U.S. Tilray Medical platform focused on research, education, cannabinoid-based medicine development, and compliant medical cannabis access rather than adult-use retail. The strategy leverages Tilray Medical's global foundation across more than 20 countries, though meaningful regulatory uncertainty remains with ongoing legal challenges.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 29, 2026 · How we verify